Welcome to our dedicated page for YD Bio SEC filings (Ticker: YDES), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
YD Bio Limited (NASDAQ: YDES) files reports with the U.S. Securities and Exchange Commission as a foreign private issuer, providing investors with detailed information on its biotechnology operations, governance, and capital markets activities. On this page, you can review YD Bio’s SEC filings, including Form 6‑K current reports that describe significant corporate events and financial disclosures related to its DNA methylation‑based cancer detection technology, ophthalmologic innovations, and clinical‑trial supply business.
Recent Form 6‑K filings referenced by the company include unaudited interim financial statements and management’s discussion and analysis for YD Bio and its subsidiary YD Biopharma, pro forma financial information following its business combination with Breeze Holdings Acquisition Corp., and press releases furnished as exhibits. Other 6‑K reports detail changes in the company’s independent registered public accounting firm, including the termination of CBIZ CPAs P.C. and the engagement of ARK Pro CPA & Co, as well as the resignation and appointment of audit committee leadership and notices related to Nasdaq director independence requirements.
Investors can also use YD Bio’s filings to track matters such as registration statements affecting the exercisability of publicly traded warrants (YDESW), disclosures about going‑concern explanatory paragraphs in prior audit reports, and information on how the company structures its reporting as a foreign private issuer under Form 20‑F. These documents help explain how YD Bio manages financial reporting, auditor relationships, and board composition while it advances programs in oncology diagnostics and limbal stem cell and exosome therapies.
Stock Titan’s SEC filings page for YDES is designed to surface these regulatory documents quickly, alongside AI‑powered summaries that highlight key points such as changes in auditors, governance updates, and links between financial disclosures and the company’s stated strategy. Users can review Form 6‑K exhibits, interim financials, and other submitted materials to better understand YD Bio’s risk factors, capital structure, and operational priorities.
YD Bio Ltd (YDES) director and CEO Dr. Ethan Shen reported an open-market purchase of 3,100 Ordinary Shares on September 9, 2026 at a weighted average price of $3.93 per share, executed in multiple transactions between $3.80 and $4.09. After this purchase, he holds 11,245,631 Ordinary Shares directly and additional shares indirectly through a trust structure of which he is the beneficial owner.
YD Bio Ltd (YDES) director and CEO Dr. Ethan Shen reported purchasing 18,378 Ordinary Shares on September 4, 2026, in the open market at a weighted average price of $3.67 per share, with individual trade prices ranging from $3.50 to $3.70.
After this transaction, Dr. Shen holds 11,242,531 Ordinary Shares directly and 43,120,858 Ordinary Shares indirectly through YD Biopharma Holding Limited and related trust entities, of which he is the beneficial owner. No Rule 10b5-1 trading plan is reported.
YD Bio Limited (YDES) filed a prospectus supplement tied to its Form F-1, covering a mixed registration: 11,436,270 ordinary shares issuable upon exercise of public warrants, 58,571,199 ordinary shares registered for resale by selling shareholders, and 3,136,056 ordinary shares issuable upon exercise of additional warrants. YD Bio’s ordinary shares trade on Nasdaq Global Market under symbol YDES, with a last reported price of $4.80 on August 28, 2026.
Attached unaudited results for the six months ended June 30, 2026 show revenue of $846,501 versus $204,007 a year earlier and a loss from operations of $3.23 million. A non-cash $9.85 million gain from the change in fair value of warrant liabilities produced net income of $6.70 million and improved total shareholders’ equity from a deficit of $(2.86) million to $4.47 million.
Cash and cash equivalents declined from $6.01 million to $2.66 million, with net cash used in operating activities of $2.82 million. Management states that recurring losses (excluding warrant fair value changes), negative operating cash flows and funding needs raise substantial doubt about the company’s ability to continue as a going concern for at least twelve months from issuance of the interim financial statements.
YD Bio Limited (YDES) reported unaudited results for the six months ended June 30, 2026. Revenue rose to US$846,501 from US$204,007 a year earlier, driven mainly by drug and medical product sales in Taiwan and technical service revenue in the United States.
Loss from operations widened to US$(3.23) million, but a US$9.85 million gain from the change in fair value of warrant liabilities produced net income of US$6.70 million (vs. a US$(1.92) million loss). Cash and cash equivalents fell to US$2.66 million from US$6.01 million, with operating activities using US$2.82 million. Management states there is substantial doubt about the company’s ability to continue as a going concern without additional financing. Warrant liabilities declined to US$4.52 million from US$14.99 million, helping turn shareholders’ equity from a US$(2.86) million deficit at December 31, 2025 to positive equity of US$4.47 million at June 30, 2026. There were 70.84 million ordinary shares outstanding at period-end.
YD Bio Limited updates its prospectus covering 11,436,270 ordinary shares issuable upon exercise of public warrants, 58,571,199 ordinary shares for resale by selling shareholders, and 3,136,056 ordinary shares issuable upon exercise of warrants.
The supplement incorporates a Form 6-K describing the launch of two chrono-nutrition nutraceutical products in Taiwan under a physician-partnership model, in collaboration with the Taiwan Chronic Disease Healthcare Association and the Future Health Institute. YD Bio’s ordinary shares trade on the Nasdaq Global Market under “YDES,” with a last reported price of $2.51 per share on August 10, 2026.
YD Bio Limited reported the launch of two nutraceutical, chrono-nutrition formulations in Taiwan as part of a new physician-partnership initiative. The products, a daytime lipid-soluble “Golden Triangle” formula and a nighttime zinc-plus-calcium formula, were co-developed with the Taiwan Chronic Disease Healthcare Association and the Future Health Institute, a physician-led health education platform with 233,000 YouTube subscribers. The company frames this as the first deployment of a repeatable physician-partnership model intended to be capital-light, generate recurring consumer revenue, and build relationships with health-conscious consumers that may support future engagement with its regulated diagnostics and clinical services offerings.
YD Bio Ltd director Lu Shao-Ta reported equity compensation activity and updated share holdings. On June 30, 2026, he exercised 5,749 restricted share units (RSUs) into 5,749 ordinary shares at a stated price of $0.00 per share and received a new grant of 5,749 RSUs.
The RSUs relate to a March 31, 2026 award under the YD Bio Limited Equity Incentive Plan with an aggregate target grant date fair value of $60,000, vesting in four equal quarterly installments based on a seven‑day volume‑weighted average price. Following these transactions, Lu holds 7,830 ordinary shares directly and 51,151 ordinary shares indirectly through his spouse.
YD Bio Ltd director Chang Kochi reported equity compensation activity involving Restricted Share Units (RSUs) and ordinary shares. On June 30, 2026, Kochi exercised 5,749 RSUs into the same number of ordinary shares at a stated price of $0.0000 per share, increasing direct holdings to 7,830 ordinary shares.
On the same date, Kochi also received a new grant of 5,749 RSUs with each RSU representing one ordinary share of YD Bio Ltd. According to the equity plan, the RSUs relate to a target aggregate grant date fair value of $60,000, vesting in four equal quarterly installments determined using a seven trading-day volume-weighted average price.
YD Bio Limited filed a post-effective amendment to its Form F-1 to register 11,436,270 Ordinary Shares issuable upon exercise of Public Warrants.
The prospectus also covers resale by selling shareholders of up to 58,571,199 Ordinary Shares and 3,136,056 Ordinary Shares issuable upon exercise of Private Warrants. The company will not receive proceeds from resale by the selling shareholders; however, cash exercise of all outstanding warrants (aggregate 14,572,326) would yield gross proceeds of up to $167,581,749. The filing updates the registration to reflect the Company’s Form 20-F for the fiscal year ended December 31, 2025 and states no additional securities are being registered under this amendment.